Literature DB >> 7888096

Catecholamine-containing biodegradable microsphere implants as a novel approach in the treatment of CNS neurodegenerative disease. A review of experimental studies in DA-lesioned rats.

A McRae1, E A Ling, S Hjorth, A Dahlström, D Mason, T Tice.   

Abstract

Biodegradable controlled-release microsphere systems made with the biocompatible biodegradable polyester excipient poly(DL-lactide-co-glycolide) constitute an exciting new technology for drug delivery to the central nervous system (CNS). Implantable controlled-release microspheres containing dopamine (DA) or norepinephrine (NE) provide a novel means to compare DA- or NE -induced restitution of function in unilateral 6-hydroxydopamine lesioned rats. A suspension of 3 microL of DA- or NE-containing microspheres or empty microspheres was implanted in 2 sites of the DA denervated striatum of rats previously unilaterally lesioned with 6-hydroxydopamine. Contralateral-rotational behavior induced by apomorphine was used as an index of lesion success and, following implantation of the microspheres, also as an index of functional recovery. Interestingly, both DA- and NE-microsphere-implanted rats displayed a 30-50% reduction in the number of apomorphine-induced rotations up to 8 wk postimplantation. Rats implanted with empty microspheres did not demonstrate significant changes in contralateral rotational behavior. Behavioral studies following implantation of a mixture of DA and NE microspheres revealed an 80% decrease in the number of apomorphine induced rotations up to 4 wk. On conclusion of the studies, immunocytochemical examination revealed growth of DA and tyrosine hydroxylase immunoreactive fibers in the striatum of DA and NE microsphere-implanted rats. Functional behavior appeared to correlate with the degree of fiber growth. Preliminary electron microscopic studies showed signs of axonal sprouting in the vicinity of the implanted microspheres. No growth was noted in rats implanted with empty microspheres. This report reviews the abilities of both microencapsulated NE and DA to assure functional recovery and to promote DA fiber (re)growth in parkinsonian rats. This novel means to deliver these substances to the central nervous system could be of therapeutic usefulness in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888096     DOI: 10.1007/BF02816119

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  40 in total

Review 1.  Applications of new drug delivery technologies to Parkinson's disease and dopaminergic agents.

Authors:  S M Stahl
Journal:  J Neural Transm Suppl       Date:  1988

2.  Collateral sprouting and reduced activity of the rat mesocortical dopaminergic neurons after selective destruction of the ascending noradrenergic bundles.

Authors:  J P Tassin; S Lavielle; D Hervé; G Blanc; A M Thierry; C Alvarez; B Berger; J Glowinski
Journal:  Neuroscience       Date:  1979       Impact factor: 3.590

3.  Survival and growth of fetal catecholamine neurons transplanted into primate brain.

Authors:  J R Sladek; T J Collier; S N Haber; R H Roth; D E Redmond
Journal:  Brain Res Bull       Date:  1986-12       Impact factor: 4.077

4.  Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists.

Authors:  M Mavridis; F C Colpaert; M J Millan
Journal:  Brain Res       Date:  1991-10-25       Impact factor: 3.252

5.  Local perfusion of noradrenaline maintains visual cortical plasticity.

Authors:  J D Pettigrew; T Kasamatsu
Journal:  Nature       Date:  1978-02-23       Impact factor: 49.962

6.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704

7.  Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum.

Authors:  J B Becker; T E Robinson; P Barton; A Sintov; R Siden; R J Levy
Journal:  Brain Res       Date:  1990-01-29       Impact factor: 3.252

8.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; T R Tice; R M Gilley
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

9.  Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue.

Authors:  A McRae-Degueurce; S Hjorth; D L Dillon; D W Mason; T R Tice
Journal:  Neurosci Lett       Date:  1988-10-17       Impact factor: 3.046

10.  Chronic intrastriatal dopamine infusions in rats with unilateral lesions of the substantia nigra.

Authors:  R Hargraves; W J Freed
Journal:  Life Sci       Date:  1987-03-09       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.